Metastatic and triple-negative breast cancer: challenges and treatment options.
Metastatic and triple-negative breast cancer: challenges and treatment options.
复制标题
DOI：
10.1007/s13346-018-0551-3
复制
发表时间：
2018-10
影响因子：
5.4
通讯作者：
Minko T
中科院分区：
文献类型：
--
作者：
Al-Mahmood S;Sapiezynski J;Garbuzenko OB;Minko T
转移性乳腺癌（MBC）治疗的主要常规类型包括手术、放射、激素疗法、化学疗法或免疫疗法。引入生物药物、靶向治疗和基因治疗可以潜在地降低MBC患者的死亡率并提高生活质量。然而，通常建议结合几种类型的治疗。三阴性乳腺癌（TNBC）占所有乳腺癌病例的10-20%，其特征在于孕酮受体（PR）、雌激素受体（ER）和人表皮生长因子受体2（HER 2）的低表达。因此，用于靶向这些受体的MBC的方便治疗对TNBC无效，因此需要特殊的治疗方法。本文就MBC的发生、预后及预测指标进行综述，并重点介绍MBC和TNBC治疗的新策略。描述了通过siRNA和吉非替尼抑制EGFR的基于纳米技术的组合方法。
The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.
登录
查看更多内容
影响因子：
--
作者：
Bertozzi S;Londero AP;Cedolini C;Uzzau A;Seriau L;Bernardi S;Bacchetti S;Pasqual EM;Risaliti A
通讯作者：
Risaliti A
影响因子：
6.2
作者：
Bailes, Adele A.;Kuerer, Henry M.;Brewster, Abenaa M.
通讯作者：
Brewster, Abenaa M.
影响因子：
4
作者：
Ahmad, Aamir;Kong, Dejuan;Wang, Zhiwei;Sarkar, Sanila. H.;Banerjee, Sanjeev;Sarkar, Fazlul H.
通讯作者：
Sarkar, Fazlul H.
影响因子：
4.6
作者：
Bhoo-Pathy, Nirmala;Verkooijen, Helena Marieke;Yip, Cheng-Har
通讯作者：
Yip, Cheng-Har
影响因子：
12.3
作者：
Alistar A;Chou JW;Nagalla S;Black MA;D'Agostino R Jr;Miller LD
通讯作者：
Miller LD